Overview

A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.

Status:
Recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to characterize safety and tolerability of romosozumab in postmenopausal women with osteoporosis and a high risk of fracture in India.
Phase:
Phase 4
Details
Lead Sponsor:
Amgen